Overview
L-carnitine is a quaternary ammonium compound synthesized endogenously from lysine and methionine and obtained from red meat and dairy. Its primary biochemical role is shuttling long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, enabling β-oxidation and ATP production.
Levocarnitine (Carnitor) is FDA-approved for primary and secondary carnitine deficiency, including dialysis-associated deficiency. Off-label and supplement use is widespread for cardiovascular disease, exercise performance, male fertility, and metabolic syndrome. Common supplement forms include L-carnitine tartrate, L-carnitine fumarate, acetyl-L-carnitine (ALCAR; better CNS penetration), and propionyl-L-carnitine (PLC; vascular endothelium effects).
Quick facts
- Mechanism
- Mitochondrial fatty acid shuttle; substrate for CPT-I/II transport system
- Primary use
- Carnitine deficiency (approved); cardiovascular, metabolic, and ergogenic research
- Evidence
- moderate
- FDA
- Approved
- Route
- Oral (tartrate, fumarate, ALCAR); IV in dialysis/deficiency
- Typical results
- Modest improvements in exercise recovery and angina; reduction in mortality after MI in some meta-analyses
Chemical information
L-Carnitine (C₇H₁₅NO₃) is a metabolic compound with a molecular weight of 161.20 g/mol. Its structural characteristics underpin its biological activity in metabolic regulation and energy homeostasis.
How L-Carnitine works
L-carnitine is required by carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane to esterify long-chain fatty acyl-CoA into acylcarnitines, which cross the inner membrane via the carnitine-acylcarnitine translocase. CPT-II then regenerates acyl-CoA in the matrix for β-oxidation. Carnitine also buffers the acyl-CoA/CoA ratio and exports excess acyl groups as acylcarnitines.
Beyond fatty acid transport, L-carnitine modulates intramitochondrial CoA homeostasis, reduces lactate accumulation under high glycolytic flux, and supports peroxisomal β-oxidation of very-long-chain fatty acids. These actions underlie its effects on exercise tolerance and metabolic flexibility.
Acetyl-L-carnitine (ALCAR) crosses the blood-brain barrier and donates acetyl groups for acetylcholine synthesis and mitochondrial energy production in neurons. Clinical interest spans diabetic neuropathy, age-related cognitive decline, and depression with metabolic features.
- Fatty acid shuttle: Required cofactor for CPT-I/II system
- CoA buffering: Maintains acyl-CoA/free-CoA ratio
- Acetyl group donor (ALCAR): Supports acetylcholine and Krebs cycle
- Endothelial effects (PLC): Improves nitric oxide bioavailability
- Insulin sensitization: Improves glucose disposal in some trials
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Oral bioavailability | 14–18% (free carnitine); ALCAR slightly higher | Saturable active transport limits absorption |
| Tmax | 3–4 hours | Slow systemic uptake |
| Half-life | ~17 hours (free); shorter for ALCAR ester | Tissue stores accumulate over weeks |
| Elimination | Renal; tubular reabsorption regulates total body stores | Increased loss in dialysis and valproate use |
Dosing & administration
L-Carnitine dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for L-Carnitine is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Nausea and GI upset
- • Diarrhea at high oral doses
- • Fishy body odor (trimethylamine production)
- • Headache
- • Insomnia with ALCAR if dosed late
Serious / potential risks
- • Seizures (especially in patients with prior seizure history)
- • Possible association with elevated TMAO and cardiovascular risk (controversial)
- • Hypotension during IV infusion
- • Hypersensitivity reactions
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Valproate | Valproate depletes carnitine, causing hyperammonemia; supplementation often required | Monitor and supplement as needed |
| Warfarin | Possible enhanced anticoagulant effect (case reports) | Monitor INR |
| Thyroid hormone | L-carnitine may blunt thyroid hormone tissue effects | Avoid in untreated hyperthyroidism; monitor in replacement |
| Antibiotics (pivalate-containing) | Increased urinary carnitine loss | Consider supplementation with prolonged use |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
L-Carnitine is a metabolic compound with research interest in fat metabolism, mitochondrial function, energy, exercise. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in fat metabolism under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Rebouche CJ.. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci (2004). doi: 10.1196/annals.1320.003 PMID: 15591001
- [2] DiNicolantonio JJ, Lavie CJ, Fares H, et al.. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc (2013). doi: 10.1016/j.mayocp.2013.02.007 PMID: 23597877
- [3] Koeth RA, Wang Z, Levison BS, et al.. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013). doi: 10.1038/nm.3145 PMID: 23563705